Posts in News
Recap of the 4th Edition of Sweet Biopharma Day

The fourth edition of Sweet Biopharma Day, which concluded successfully on October 9 at Espace Tonik in Sainte-Julie, once again showcased the vitality and collaborative spirit of Quebec's biopharmaceutical industry. Organized by adMare BioInnovations, AmorChem, BIOQuébec, CQDM, and the Fonds de solidarité FTQ, this invitation-only event allowed 16 innovative companies to present their projects to a prestigious audience, composed of influential industry representatives.

Read More
New Facilities for Biodextris

On October 4th, Biodextris, a member of BIOQuébec, inaugurated its brand-new facilities, made possible through an investment of nearly $25 million. These state-of-the-art infrastructures are designed to support the development of complex bioprocesses and biological products, further solidifying the company's role in life sciences innovation in Quebec.

Read More
Second close of financing

MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics is delighted to announce the Quebec Government’s investment of $1.38 million via its Impulsion PME program, for which Investissement Québec acts as agent. With the addition of angel investors, this brings the total funding to $2.9 million needed for Neurenati to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease affecting approximately 1,300 newborns in North America each year.

Read More
ExCellThera Announces Publication in Blood Highlighting the Potential for UM171 to Result in Efficient Stem Cell Expansion for Therapeutic Use

MONTREAL, February 1, 2024 – ExCellThera Inc. (ExCellThera), a world leader in enhanced blood stem cell therapies, announced today a publication in the journal Blood that further elucidates the UM171 mechanism of action and highlights the potential for UM171 to result in the efficient expansion of stem cells with preserved function for therapeutic use.

Read More
ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy

MONTREAL, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today positive results from 50 patients in two multi-center Phase 2 trials for UM171 cell therapy conducted at transplant centers in the U.S., Canada and Europe, building on prior strong data from a Phase 1/2 trial and comparative registry studies (CIBMTR and EBMT).

Read More
CASTL launches national biomanufacturing training program powered by Upskill Canada

(Charlottetown, PE –November 27, 2023) – Today, the Canadian Alliance for Skills and Training in Life Sciences (CASTL) announces the launch of its national biomanufacturing skills and training program – CASTL Elevate. CASTL Elevate is powered by Upskill Canada, and is part of the first wave of partnership programs that are taking an industry-informed approach to supporting workers in Canada’s fast-growing biomanufacturing sector.

Read More
Linearis Opened its New Laboratory

Québec, Canada, November 28, 2023- Linearis Labs Inc (“Linearis”), an innovative company at the intersection of AI and biomarker analysis, announces today the inauguration of its new laboratory facilities at a site formerly occupied by Medicago Inc (“Medicago”). Following the announcement of the cessation of their operations after 26 years, Linearis acquired over 650 scientific instruments and hired some of their most seasoned specialized personnel in mass spectrometry, quality assurance, and laboratory management.

Read More
NovaScience program: call for projects Support for the position of innovation and commercialization manager

The Ministère de l’Économie, de l’Innovation et de l’Énergie is issuing a call for projects to meet the innovation and commercialization needs of businesses and organizations, to help them become more competitive, ensure their growth and productivity, and integrate a culture of innovation into their practices, by creating a position of innovation and commercialization manager.

Read More
McGill University and Moderna to expand collaborations with new projects in Lipid Nanoparticle research

McGill University today announced it has signed agreements with ModernaTX, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to support two innovative research projects in the area of lipid nanoparticles (LNPs). LNPs are critical components in mRNA medicines such as vaccines, as they are the primary delivery method of mRNA strands to the target cells.

Read More
Health Research Foundation Launches Call For Nominations For New Diversity and Equity in Research Award

Ottawa, May 31, 2023 – The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that nominations are now open for the 2023 Diversity and Equity in Research Award. This new award recognizes a remarkable individual whose research demonstrates the highest quality of excellence and advances equitable participation in health research and access to health care in Canada, improving the well-being of all Canadians, particularly those facing inequities.

Read More
GSK completes acquisition of BELLUS Health

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the “Arrangement”). The Arrangement was approved by BELLUS’ shareholders on 16 June 2023.

Read More